Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR); Staying Put Despite Q2 Disappointment

August 1, 2012 9:54 AM EDT Send to a Friend
Get Alerts OPTR Hot Sheet
Price: $12.78 --0%

Rating Summary:
    4 Buy, 9 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 16 | Down: 12 | New: 33
Trade OPTR Now!
Join SI Premium – FREE
Baird maintains an 'Outperform' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $18.00 (from $19.00).

Aanlyst, Thomas Russo, said, "Sticking with OPTR following disappointing Q2 report. We expect the stock could remain under pressure from the first meaningful Dificid miss, including a down June to end the quarter. Biotech launch stories aren’t known for instilling patience, but we aren’t prepared to view one bad month, with possible contributing factors, as indicative of a fundamental change, particularly when quantitative comments on July suggest a strong bounce-back. We expect a return to better results and wouldn't sell on weakness here."

FY12 EPS estimate cut from (0.96) to (1.11) and FY12 from (0.78) to (1.32)

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $13.66 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Robert W Baird

Add Your Comment